Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tysabri Out Of Remission; Returns With Updated Indication, Risk Management

Jun 12 2006

• By The Pink Sheet

Related Content

GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away

Jun 10 2002

Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial

Mar 07 2005

Tysabri Cohort Study May Need Internal Control Group For Useful Results

Mar 13 2006

Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised

Mar 13 2006

Tysabri Return To Market With Expanded Indication Backed By Committee

Mar 13 2006

Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost

Jun 12 2006

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window